Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
November 20, 2023
Please see attachment.
Contact information
Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com
Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com
Attachment
